
    
      Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the
      safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard
      therapy.

      Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the
      progression-free survival of the MM-121 + standard therapy.
    
  